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This article examines the diffeomorphometry of magnetic resonance imaging-derived structural markers
for the amygdala, in subjects with symptomatic Alzheimer’s disease (AD). Using linear mixed-effects
models we show differences between those with symptomatic AD and controls. Based on template
centered population analysis, the distribution of statistically signiﬁcant change is seen in both the vol-
ume and shape of the amygdala in subjects with symptomatic AD compared with controls. We ﬁnd that
high-dimensional vertex based markers are statistically more signiﬁcantly discriminating (p < 0.00001)
than lower-dimensional markers and volumes, consistent with comparable ﬁndings in presymptomatic
AD. Using a high-ﬁeld 7T atlas, signiﬁcant atrophy was found to be centered in the basomedial and
basolateral subregions, with no evidence of centromedial involvement.
 2015 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Magnetic resonance imaging (MRI) studies have substantially
advanced our knowledge of brain atrophy in Alzheimer’s disease
(AD). MRI measures are an indirect reﬂection of the neuronal injury
that occurs in the brain as the AD pathophysiological process
evolves. Several MRI measures are known to be altered among in-
dividuals with AD dementia or mild cognitive impairment (MCI). In
the initial stages of AD, atrophy appears to have a predilection for
brain regions in the medial temporal lobe with heavy deposits of
neuroﬁbrillary tangles (Arnold et al., 1991; Braak and Braak, 1991;
Price and Morris, 1999). Consistent with this pattern of neuroﬁ-
brillary pathology, the volume of the entorhinal cortex and hip-
pocampus have been shown to discriminate patients with AD
dementia or MCI versus cognitively normal subjects and to beC BY-NC-SA license (http://
cience, The Johns Hopkins
USA. Tel.: þ1 410 516 3826;
Published by Elsevier Inc. All righassociated with likelihood of progression from MCI to AD dementia
(Atiya et al., 2003; Kantarci and Jack, 2004).
To date, most MRI studies of subcortical gray matter nuclei have
deﬁned a single measure of structural volume (Bossa et al., 2011;
McEvoy et al., 2011; Roh et al., 2011). Although this has the
advantage of being quantitative, it does not give speciﬁc informa-
tion about subregions of atrophied nuclei. This information would
be useful to determine whether morphometric results correlate
with neuropathologic studies, deﬁne better the subregional distri-
bution of atrophy, and correlate pathologic changes with clinical
features of AD.
Diffeomorphometry and geodesic positioning in computational
anatomy (Miller et al., 2014) for the study of the distribution of
functional and structural change in neurodegeneration has already
proved to be very powerful. Statistical shape analysis has been
useful for studying normal age-related changes in subcortical
nuclei, and a number of other diseases (Ashburner et al., 2003;
Csernansky et al., 1998, 2000; Qiu et al., 2010; Thompson et al.,
2004; Wang et al., 2007). The study described here follows our
previous work (Miller et al., 2013), in which we used diffeo-
morphometry to measure subregional atrophy in 3 temporal lobets reserved.
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jects with preclinical AD, that is, individuals whowere clinically and
cognitively normal at the time of their MRI scans. This approach
allows for a ﬁne-scale high-dimensional analysis of nonuniform
change patterns in the structures and complements coarser mea-
sures, such as measures of total volume. Despite its proximity to the
hippocampus, relatively little is known about the role of amygdala
in MCI and AD. Following earlier histopathologic ﬁndings
(Arriagada et al., 1992; Herzog and Kemper, 1980; Scott et al., 1991,
1992; Tsuchiya and Kosaka, 1990), neuroimaging studies of AD
patients suggest that amygdala volume may correlate with that of
the hippocampus (Poulin et al., 2011). Further, recent shape analysis
(Cavedo et al., 2011; Qiu et al., 2009) suggests there is substantial
atrophy within the amygdala in AD.
The study described here focuses on the examination of the
amygdala via diffeomorphometry. By mapping features across co-
ordinate systems, it was possible to identify morphometric changes
obtained in 1.5 T scans within high-ﬁeld 7T parcellations of the
amygdala. We demonstrate that the location of statistically signif-
icant change is distributed across the core amygdala, including the
basolateral and basomedial nuclei, in subjects with symptomatic
AD compared with controls.
2. Methods
2.1. Study design
In the present study, known as the BIOCARD study, all subjects
were cognitively normal when they were recruited. The mean age
of the BIOCARD subjects at baseline was 57.1 years. MRI scans were
acquired during the period 1995e2005. The participants have now
been followed for up to 17 years. Table 1 provides summary of the
demographic characteristics of the subjects.
2.2. Selection of participants
A total of 354 individuals were initially enrolled in the study.
Recruitment was conducted by the staff of the Geriatric Psychiatry
branch of the Intramural Program of the National Institute of
Mental Health (NIMH). Subjects were recruited via printed adver-
tisements, articles in local or national media, informational lec-
tures, or word-of-mouth. The study was designed to recruit and
follow a cohort of cognitively normal individuals who were pri-
marily inmiddle age. By design, approximately three quarters of the
participants had a ﬁrst degree relative with dementia of the Alz-
heimer type. The overarching goal was to identify variables among
cognitively normal individuals that could predict the subsequent
development of mild to moderate symptoms of AD. Toward that
end, subjects were administered a comprehensive neuropsycho-
logical battery annually. MRI scans, cerebrospinal ﬂuid, and blood
specimens were obtained approximately every 2 years. The study
was initiated at the NIMH in 1995 and was stopped in 2005. In
2009, a research team at the Johns Hopkins School of Medicine was
jointly funded by the National Institute on Aging (NIA) and NIMH to
reestablish the cohort, continue the annual clinical and cognitiveTable 1
Participant characteristics stratiﬁed by outcome status
Variable Control group
(N ¼ 230)
Age at time of baseline MRI scan, mean
number of years (SD)
55.4 (9.8)
Gender, females (%) 61
Key: AD, Alzheimer’s disease; MCI, mild cognitive impairment; MRI, magnetic resonanceassessments, collect blood, and evaluate the previously acquired
MRI scans, cerebrospinal ﬂuid, and blood specimens. To the best of
our knowledge, this is the only study in participants who were
cognitively normal at entry, with this set of measures, and with
such a long duration of follow-up.
At baseline, all participants completed a comprehensive evalua-
tion at the Clinical Center of the National Institutes of Health (NIH).
This evaluation consisted of a physical and neurologic examination,
an electrocardiogram, standard laboratory studies (e.g., complete
blood count, vitamin B12, thyroid function, and so forth), and neu-
ropsychological testing. Individuals were excluded from participa-
tion if they were cognitively impaired, as determined by cognitive
testing, or had signiﬁcant medical problems such as severe cere-
brovascular disease, epilepsy, or alcohol or drug abuse. Five subjects
didnotmeet theentrycriteria andwereexcludedat baseline, leaving
a total 349 participants who were followed over time.
2.3. MRI assessments
TheMRI scans acquired at theNIHwere obtained using a standard
multimodal protocol using GE 1.5 T scanner. The scanning protocol
included localizer scans, axial fast spinecho sequence (repetition time
[TR] ¼ 4250, echo time [TE] ¼ 108, ﬁeld of view [FOV] ¼ 512  512,
thickness/gap ¼ 5.0/0.0 mm, ﬂip angle ¼ 90, 28 slices), axial ﬂuid-
attenuated inversion recoverysequence (TR¼9002, TE¼157.5, FOV¼
256  256, thickness/gap ¼ 5.0/0.0 mm, ﬂip angle ¼ 90, 28 slices),
coronal spoiledgradientecho (SPGR)sequence (TR¼24,TE¼2, FOV¼
256  256, thickness/gap ¼ 2.0/0.0 mm, ﬂip angle ¼ 20, 124 slices),
and sagittal SPGR sequence (TR ¼ 24, TE ¼ 3, FOV ¼ 256  256,
thickness/gap 1.5/0.0 mm, ﬂip angle ¼ 45, 124 slices). The analyses
described here used the coronal SPGR scans. A total of 805 scanswere
acquired from the participants with a mean of 2.4 scans per person.
2.4. Clinical and cognitive assessment
The clinical and cognitive assessments of the participants have
been described elsewhere (Moghekar et al., 2013). The cognitive
assessment consisted of a neuropsychological battery covering all
major cognitivedomains (i.e.,memory, executive function, language,
spatial ability, attention, and processing speed). A clinical assess-
ment was also conducted annually. This included the following: a
physical and neurologic examination, record of medication use,
behavioral and mood assessments, family history of dementia, his-
tory of symptom onset, and a Clinical Dementia Rating (CDR), based
on a semi-structured interview (Hughes et al., 1982; Morris, 1993).
2.5. Consensus diagnoses
Each case included in these analyses has received a consensus
diagnosis by the staff of the BIOCARD Clinical Core at Johns Hopkins.
This research team included: neurologists, neuropsychologists,
research nurses, and research assistants. During the study visit,
each subject had received a comprehensive cognitive assessment
and a CDR, as well as a comprehensive medical evaluation
(including a medical, neurologic, and psychiatric assessment).MCI during scan
(N ¼ 9)
AD dementia during
scan (N ¼ 7)
64.3 (9.96) 63.8 (8.04)
33 57
imaging; SD, standard deviation.
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clinical summary was prepared that included information about
demographics, family history of dementia, work history and past
history of medical, psychiatric, and neurologic disease, medication
use, and results from the neurologic and psychiatric evaluation. The
reports of clinical symptoms from the subject and collateral sour-
ces, based on the CDR, were summarized, and the results of the
neuropsychological testing were reviewed. Thus, the diagnostic
process for each case was handled in a similar manner: (1) clinical
data were examined pertaining to the medical, neurologic, and
psychiatric status of the subject; (2) reports of changes in cognition
by the subject and by collateral sources were examined; and (3)
decline in cognitive performance was established. These data were
used to: (1) determine whether the subject had become cognitively
impaired; (2) determine the likely etiology of any impairment; and
(3) determine the age at which the clinical symptoms began, based
primarily on the reports of clinical symptoms from the subject and
from collateral sources. These diagnostic procedures are identical to
those implemented in the Alzheimer’s Disease Research Centers
program, supported by the NIA. It is acknowledged that, as this
process is dependent on the clinical and cognitive data available at
any one point in time, some subjects who are diagnosed as having
MCI may subsequently be diagnosed as normal or as impaired not
MCI. This represented 4 of the subjects in the total sample.
During the acquisition of the scans at the NIH, 7 subjects were
diagnosed with dementia of Alzheimer’s type (DAT), and 9 subjects
were diagnosed with MCI. We term this set of subjects the
“symptomatic” cohort, that is, subjects who had MCI or DAT at the
time the scans were taken. Four or more years later, when the study
was re-initiated at Johns Hopkins, an additional number of subjects
had developed MCI or DAT. During the entire period, 230 subjects
continued to be cognitively normal whomwe deﬁned as the control
group. In the analyses described in the following (Section 2.8.3.4),
we included age and gender as covariates to adjust for any differ-
ences in these parameters between the groups.2.6. Region-of-interest analysis
Statistical shape analysis requires a preliminary alignment phase,
which produces a high-dimensional representation in a ﬁxed coor-
dinate system. A common approach in this framework is to register
all shapes to a single one, called the template, deﬁning each anatomy
by its position relative to the template. This is achieved via diffeo-
morphic mappingmethods. It is important, in this context, to ensure
that the template is as close as possible to the population, and it will
be deﬁned as representing the population average.Fig. 1. Left: surface reconstruction of amygdala (green), entorhinal cortex (red), hippocamp
with reconstructed structures embedded in the MRI volume. Abbreviation: MRI, magneticIn each scan, the amygdala was segmented using the land-
mark region-of-interest template-based Large Deformation Dif-
feomorphic Metric Mapping (LDDMM) pipeline comparable with
previous work (Csernansky et al., 1998; Munn et al., 2007). A
representative elderly cognitively normal subject was selected as
the template, and left and right structures were segmented
manually. The principal axis was identiﬁed by placing the head
landmark at the center of the inferior boundary of the entorhinal
sulcus (on the most anterior coronal plane showing the limen
insula), with the tail landmark placed at the center of the most
caudal aspect of the basomedial nucleus (on the most caudal
coronal plane showing the amygdala). Equidistant sections were
selected perpendicular to this principal axis, with landmarks on
each section placed at the dorsal lateral and dorsal medial extent
of the amygdala, and at an intermediate point on the dorsal
amygdala boundary, as well as at the ventral lateral and ventral
medial extents of the amygdala, and intermediate point on
ventral amygdala boundary. Please see http://caportal.cis.jhu.edu/
wiki/tutorials/amygdala/amygdala.html for a description of the
landmark placements. Inter-rater reliability for 9 scans yielded a
mean kappa score of 80.95 for left and right segmentations.
Landmarks encompassing the amygdala were used to calcu-
late a rigid transformation (Umeyama, 1991) between the tem-
plate followed by LDDMM landmark matching (Joshi and Miller,
2000) and image matching (Beg et al., 2005). These trans-
formations were subsequently used to move the template seg-
mentation onto each subject’s MR scan yielding segmentations
for each subject.
Segmentations were individually inspected, manually corrected
where necessary and then converted into triangulated surfaces
using the open source iso2mesh software. Fig. 1 shows the amygdala
relative to the hippocampus and entorhinal cortex and their
embedding in a section in one subject.2.7. Amygdalar nuclei parcellation
A 7T MRI scan of resolution 0.8 mm was used to reconstruct
high-ﬁeld parcellation of the population amygdala. The 7T sub-
ject is a 42-year-old male who is healthy by self-report. The
subject was scanned using a standard MPRAGE protocol in a
Philips Achieva 7.0 T scanner (TR ¼ 4.3 ms, TE ¼ 1.95 ms, ﬂip
angle ¼ 7, FOV ¼ 220  220  180). The amygdala was sub-
divided into 4 nuclei: lateral, basolateral, basomedial, and cen-
tromedial nuclei using deﬁnitions based on the Paxino Atlas of
the Human Brain (Mai et al., 2004) and illustrated in detail at
http://caportal.cis.jhu.edu/wiki/tutorials/amygdala/amygdala.html.us (blue), ventricle (gray) from one BIOCARD subject. Right: corresponding MRI section
resonance imaging.
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morphometry
2.8.1. Template averaging
Using rigid registration (rotation and translation) each amyg-
dalar surface (from Section 2.6) was aligned to a common spatial
position. Rigid registration computes an optimal transformation
between vertices of 2 surfaces S0 and S1, by minimizing a score
combining registration and soft assignment, given by:.
Fðw;R; TÞ ¼
Z
S1S2
wðx; yÞkRxþ T  yk2ds1ðxÞds2ðyÞ
þ l
Z
S1S2
wðx; yÞln wðx; yÞds1ðxÞds2ðyÞ
Here, R and T are a rotation matrix and a translation vector,
respectively; s1 and s2 are area forms on S1 and S2, respectively; and
w is a soft assignment function deﬁned on S1 S2, which is positive
and satisﬁes
R
S1wðx0; yÞds1ðxÞ ¼
R
S2wðx; y0Þds2ðy0Þ ¼ 1 for allðx; yÞ˛S1  S2. Right subvolumes were ﬂipped before alignment to
facilitate comparison of left and right structures inﬁxed coordinates.
The rigidly aligned volumes were used to generate a population
template (Maetal., 2010)basedonagenerative shapemodel, inwhich
an observed surface is modeled as a random deformation of a tem-
platewithadditivenoise.Given thismodel, thepopulation template is
estimated from the surface population data using the mode approx-
imation to the EM algorithm, subject to the topology constraints that
the population template is a diffeomorphic transformation of a ﬁxed
reference shape called the hypertemplate. In the Bayesian viewpoint,
thepopulation template is consideredasa randomdeformationof the
hypertemplate. The population template becomes the coordinate
system and is computed by applying the algorithm to the population
of 173 baseline scans and is therefore blind to labels.
2.8.2. LDDMM surface registration
Non-rigid registration between the population template and all
surfaces is done via LDDMM surface registration (Vaillant and
Glaunes, 2005) which computes a smooth and invertible trans-
formation that deforms the template to a surface that is very close
to the target. More precisely, it minimizes a 2-term energy function
taking the form
E ¼ Distshape

Stemp; Sdef
2 þ l ErrorSdef ; Sobs
where Stemp is the population template surface, Sobs is the observed
surface, and Sdef is the deformed population template. The ﬁrst
term, Distshape, is a geodesic distance in shape space, which com-
putes and optimizes a least-deformation path between 2 surfaces,Fig. 2. High-ﬁeld 7T amygdala template (left) mapped into BIOCARD 1.5 T population coord
basomedial (sky-blue), centromedial (caramel) and lateral (red). These nuclei will be deno
subﬁeld parcellation of the 1.5 T population BIOCARD atlas generated by transferring the lathe distance being given by the optimal deformation cost (Vaillant
and Glaunes, 2005). The second error term computes a norm be-
tween surfaces. The construction is based on the representation of
surfaces as geometric currents.
2.8.3. Shape statistics
During the preprocessing phase, each subject’s left structurewas
registered to the template, resulting in the computation, at each
vertex k of the template surface, and for each subject s, of a defor-
mation marker Yk(s) that measures the expansion and/or atrophy at
vertex k in subject s relative to the template. This is deﬁned as the
logarithm of the local expansion and/or reduction in surface area
around vertex k entailed by template registration and can be
interpreted mathematically as a log-jacobian on the population
template surface. See Figs. 3e5 for examples of suchmarkers. These
markers were then transformed into a sequence of shape indicators
at different resolution as follows:
2.8.3.1. High resolution. The vertex Jacobian marker Yk(s), which
has 750 dimensions associated to the number of vertices.
2.8.3.2. Projection on Laplace-Beltrami eigenbasis. The ﬁrst 25 ei-
genvectors of the surface Laplacian are computed (on the popula-
tion template) and the 25-dimensional projection of the surface
log-Jacobian of the deformation.
2.8.3.3. High-ﬁeld deﬁned subnuclei markers. Four amygdala sub-
ﬁelds are deﬁned from the 7T high-resolution images, which are
mapped onto the population template using LDDMM surface
matching. This transports the labelled high-ﬁeld template to the
population template allowing the labeling of the vertices. The dif-
feomorphic surface mapping generates the bijection between the
1.5 T population template and the high-ﬁeld 7T atlas on the con-
tinuum of the 3D coordinate system allowing us to transfer the
labeled information between the 2 coordinate systems. The tem-
plates were highly sampled so that vertices are small, thereby
allowing precise transfer of information between the vertices of the
2 coordinate systems as deﬁned by the diffeomorphic bijection as
shown in Fig. 2. The labeled vertices of the subﬁelds are used to
develop an integrated Jacobian marker for each of the 4 nuclei
basolateral, basomedial, centromedial and lateral. These nuclei will
bedenotedbelowas1, 2, 3 and4 respectively. This is a 4-dimensional
marker shown in Fig. 3. Note that the values are all positive, indi-
cating that group difference is only associated with atrophy.
Global: logarithm of the structure volume.2.8.3.4. Linear mixed-effects model. The statistical analyses com-
pared subjects with symptomatic AD (i.e., subjects with MCI and AD
dementia) versus cognitively normal individuals. The analysesinates (middle); regions correspond to parcellation into 4 subnuclei: basolateral (blue),
ted below as 1, 2, 3 and 4 respectively. The right column shows a labeling into the 4
bels in the closest vertex in the middle column to the 1.5 T coordinate system.
Fig. 3. Statistically signiﬁcant family wise error rate (FWER) at 5% signiﬁcance for the mixed effects modeling of the symptomatic group compared with controls, demonstrating
atrophy for left and right amygdala. Left panel shows statistics depicted from medial-rostral aspect; right panel shows depiction from medial-caudal aspect. Statistically, signiﬁcant
vertex coloring given by the natural log of the surface Jacobian bþ b0a indexed over the template between the control versus symptomatic groups corrected at the average age. For
reference only, shown are entorhinal cortex, hippocampus, and lateral ventricle.
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computed statistics at each vertex of the template surface, corrected
for multiple comparisons, using permutation tests.
Our statistical model is a linear mixed-effects model in which
the noise associated with the scans from the same subject is
modeled as different than the noise associated cross-sectionally in
averaging to the common template. Hence the term “mixed-ef-
fects”. So we introduce group variables g(s) equal to 1 if subject s
belonged a disease group and 0 otherwise. These disease groups
will be MCI, AD, MCI þ AD for the symptomatic classiﬁcation. We
then use the linear statistical model deﬁned as.
Yvj

s
 ¼ av þ a0vajsþ bv þ b0vajsgsþ gvcsþ dvds
þ εvj

s

where s denotes subjects/structure; j represents scan order in the
subject’s time series; v indexes the multivariate marker (v is be-
tween 1 and 1, 4, 7, 25, or 750); Yvj(s) is the vth coordinate of
deformation marker for subject s at scan j; aj(s) is the subject’s age
at scan j; g(s) is the subject’s group (control or disease); c(s) and d(s)
are covariates and respectively denote the subject’s intracranial
volume and gender; εvj(s) represents the noise, modeled as εvj(s) ¼
hv(s) þ zvj(s) where hv(s) measures between-subject variation and
zvj(s) measures within-subject variation. Both noise are assumed to
be centered Gaussian, with variance rs2v and s
2
v , respectively.
The parameters av;a0v;bv;b
0
v;gv; dv; s
2
v and r are estimated by
maximum-likelihood. The estimation procedure is iterative and
alternates the following 2 steps until convergence (which usually
happens after a small number of iterations).
Step 1: Least square estimation, updating all parameters with
ﬁxed r. Let n denote the number of subjects, Ns the number of scans
for subject s, and N the total number of scans (the sum of all Ns). Let
d be the number of variables in the linear model (d ¼ 6 in our case)
and K the dimension of the shape marker. Rewrite the linear model
in the form: Y(s) ¼ X(s)q þ ε(s) where Y(s) is a Ns  Kmatrix, X(s) is
Ns d and q is d K. Deﬁne thematrices SXX ¼
Pn
s¼1XðsÞTXðsÞ and
SXY ¼
Pn
s¼1XðsÞTYðsÞ. Deﬁne also XðsÞ ¼
PNs
j¼1XjðsÞ where Xj(s) is
the jth row of X(s), and similarly YðsÞ ¼ PNsj¼1YjðsÞ to set.
SXX ¼ r
Xn
s¼1
XðsÞTXsð1þ NsrÞ
and
SXY ¼ r
Xn
s¼1
XðsÞTYsð1þ NsrÞ
Then, the least square estimator of q is given byq ¼

SXX  SXX
1
SXY  SXY

To estimate the variance, deﬁne the residual R(s) ¼ Y(s)  X(s)q,
which is an Ns Kmatrix. For a given v, letRvðsÞ ¼
PNs
j¼1RjvðsÞ. Then
s2v ¼
1
N
Xn
s¼1
kRvðsÞk2  rN
Xn
s¼1
RvðsÞ2
1þ rNs
Step 2: Update rwith all other parameters ﬁxed. Compute, with
the notation mentioned previously.
[

s
 ¼ 1
K
XK
v¼1
RvðsÞ2
s2v
Then, br is deﬁned as the minimizer of.
br ¼ argminr  rXn
s¼1
[ðsÞ
1þ rNs þ
Xn
s¼1
logð1þ rNsÞ
This minimization has no closed-form solution and must be
performed numerically.
Note that this model assumes that r is independent of the shape
coordinate, v. Although extending this algorithm to a coordinate-
dependent parameter would be straightforward, we have
preferred not to do so to avoid the computational burden of per-
forming K nonlinear optimization procedures at each step
mentioned previously, especially in the context of permutation
tests that are used to estimate p-values.
After convergence, the log-likelihood is given by (up to an ad-
ditive constant)
L ¼ N log

s2

þ
Xn
s¼1
logð1þ rNsÞ
2.9. Analysis with familywise error rates
For each type of shape marker, we perform an omnibus test for
the signiﬁcance of the group variables, by testing the null hypoth-
esis H0ðvÞ : bv ¼ b0v ¼ 0. The test statistic is the likelihood ratio
between the compared models. The set of coordinates v for which
the null hypothesis is rejected is computed via permutation tests
and corrected for multiple comparisons within the shape marker
(no correction is made across shape markers, because these are
highly correlated).
Letting F denote the log-likelihood ratio, the maximum value
over all vertices, F* ¼ max
v
Fv, is compared with those obtained by
performing the same computation several times, with group labels
randomly assigned to subjects. The p-value is given by the fraction
Table 2
Differences between controls and symptomatic subjects
Groups Side Vertex Laplace 7T regions Volume
Controls versus
symptomatic cases
Left <0.00001 0.002 0.0047 (1,2) 0.004
Controls versus
symptomatic cases
Right 0.0001 0.005 0.01 (1,2,4) 0.002
Rows 2 and 3 show p-value resulting from linear mixed effects model analysis of con-
trols versus the combined group of symptomatic cases listed from high to low dimen-
sion. Columns list p-value for the vertex (750 dimensions per structure), and Laplace-
Beltrami eigenvectors (25 dimensions per structure), the four 7T regions, and volume
biomarkers (1 dimension per structure). Regions in the 7T template are signiﬁcant at
0.05 FWER after correcting formultiple comparisons. p-value testing based on geometry
segment clustering gives p-values of 0.028 and 0.002 for left and right, respectively.
(1, 2) basolateral and basomedial, (1,2,4) basolateral, basomedial and lateral nuclei.
Key: FWER, familywise error rates.
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the value obtained with the true groups. Similarly, p-values are
obtained for the volume except that no multiple testing correction
is needed.
Permutation testing provides a (conservative) estimate of the set
of vertices v on which the null hypothesis is not valid. This set is
deﬁned by D ¼ fv : Fv  qg where q* is the 95 percentile of the
observed value of F* over the permutations (Nichols and Hayasaka,
2003). These results are visualized by coloring the vertices that
were signiﬁcant with an atrophymeasure deﬁned asðbv;0 þ bvageÞ,
where bv;0; bv are the coefﬁcients associated to the group variable in
the regression model for vertex v, and age is the average age in the
considered disease group population.
3. Results
The results of the mixed effects models comparing the con-
trols and the symptomatic cases, taken together as a group, are
shown in Table 2, which provides the p-values for shape change
between the groups, as measured by the high-dimensional shape
markers, based on the Jacobian statistics at the vertices and
Laplace Beltrami expansions, and the low-dimensional volumeFig. 4. Results ofmixed effectsmodeling of the symptomatic group comparedwith controls. To
anddegree of atrophy shownas a percentdecrease relative to the template (right) for the7Tregi
nuclei. Blue color in theﬁgure on the left implies that the vertex statistic is not signiﬁcant for FW
Jacobian ¼ 1). Abbreviation: FWER, familywise error rates.markers. As can be seen, the high-dimensional vertex based
markers are statistically more signiﬁcantly discriminating (p <
0.00001) than lower-dimensional markers and volumes. To more
easily visualize the location of these signiﬁcant differences, the
p-values are superimposed on a template of the amygdala,
showing the location of maximum difference between the groups
(see Fig. 4). Note that the images show the amount of surface
atrophy relative to the template, which is expressed in percent-
ages, 100% meaning no difference with template. The red value of
85% means, in terms of the atrophy measure, there has been a
change (a net decrease) of 15% from the original template to the
disease group at 85%.
In addition, Fig. 5 shows the location of the signiﬁcant differ-
ences between the controls and the symptomatic cases in relation
to the nuclei of the amygdala, using a high-ﬁeld 7T atlas. Signiﬁ-
cance is determined at 0.05 familywise error rates, based on Bon-
ferroni bound p < 0.0125. The top row shows the left amygdala
subregions with the basomedial (p ¼ 0.0006) and basolateral (p ¼
0.0024) signiﬁcant, with no signiﬁcance for the lateral (p ¼ 0.036)
and centromedial (p ¼ 0.103) subregions. The bottom row shows
the right amygdala, showing statistically signiﬁcant subregions,
basomedial (p ¼ 0.0087), basolateral (p ¼ 0.0047), lateral (p ¼
0.0045), with no signiﬁcance centromedial (p ¼ 0.0565).
Thus, signiﬁcant atrophy was centered in the basomedial and
basolateral subregions, with no evidence of centromedial
involvement.
Table 3 provides the p-values for the MCI and the AD dementia
cases, taken separately, comparedwith the controls. The differences
between the AD cases and the controls are statistically signiﬁcant
for both left and right hemisphere. The differences between theMCI
cases and the controls, while in the same direction, are not signif-
icant for all markers.4. Discussion
The examination of amygdalar shape analysis in this cohort has
revealed volumetric changes as well as non-uniform shape changesp and bottom rows portray left and right amygdala respectively, showing the p-value (left)
onsprojectedonto the signiﬁcant high-ﬁeld regions, that is, thebasolateral and basomedial
ER 5%. Blue in theﬁgure on the right implies no atrophy relative to template (determinant
Fig. 5. Results of mixed effects modeling of the symptomatic group compared with the controls. The ﬁgures in the left column show the 7T high-ﬁeld left amygdala template (top
row) with 4 subﬁelds deﬁned from the 0.8 mm isotropic 7T MRI; the bottom row shows right high-ﬁeld amygdala. The ﬁgures in the right column show the subﬁelds transferred to
the 1.5 T population template showing statistically signiﬁcant subregions. Signiﬁcance is determined at 0.05 FWER, based on Bonferroni bound p < 0.0125. Abbreviations: FWER,
familywise error rates; MRI, magnetic resonance imaging.
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high-ﬁeld amygdala atlas, signiﬁcantly atrophied subregions were
located speciﬁcally in the basomedial and lateral nuclei. This is
consistent with the histopathologic ﬁndings with the greatest cell
packing density loss in themedial region and some loss in the lateral
region (Herzog and Kemper, 1980). It is also interesting that the re-
gion of signiﬁcant atrophy illustrated in Figs. 3e5 is identical to that
observed in autopsied amygdala with AD (Scott et al., 1991), that is,
superiorly adjacent to the paralaminar region. The same study
showed great loss of “large nerve cells” in themagnocellular regions
of the amygdalawhich is deep inside the basomedial nucleus. This is
consistent with the hypothesis that the observed changes in the
surface of the basomedial nucleus reﬂect the underlying changes.
Our results can be interpreted in terms of the core and non-core
amygdalar parcellations by Price. (1987), (2003) based on subregions
sharingdevelopmental, structural, and functional characteristics. Core
amgydala consists of the lateral, basal, and accessory basal nuclei, and
the non-core amygdala consists of remaining nuclei including the
central, medial, and cortical nuclei (Munn et al., 2007; Sheline et al.,
1998). From a functional standpoint, subnuclei in the core amygdala
are associated with a role in emotional processing and storage of
emotional memories (LeDoux and Schiller, 2009; Price, 1981), which
provide clues as to how they may be affected in MCI and AD.
The volumetric changes are consistent with those observed in a
recent study (Poulin et al., 2011) of 2 large samples of MCI and ADTable 3
Differences between controls (NC) and MCI subjects (rows 2, 3) and AD dementia
subjects (rows 4, 5)
Groups Side Vertex Laplace 7T regions Volume
MCI versus NC Left 0.01242 0.004 0.0695 0.118
MCI versus NC Right 0.067325 0.030 0.0746 0.097
AD versus NC Left <0.00001 0.005 0.0003 (1,2) 0.002
AD versus NC Right 0.0002 0.005 0.0089 (1,4) 0.002
p-value testing based on geometric segments was signiﬁcant for the AD dementia
cases, left and right p-value 0.024 and 0.002, respectively.
(1,2) basolateral and basomedial (1,4) basolateral and lateral nuclei.
Key: AD, Alzheimer’s disease; MCI, mild cognitive impairment; NC, healthy controls.cases. The non-uniform changes in shape may explain the variation
in volume in the relatively few neuroimaging studies of amygdala in
MCI and AD. The lateral part of the amgydala has also been noted in
recent shape analysis by Cavedo et al. (2011) and Qiu et al. (2009).
The former study is pertinent because a diffeomorphic approach
was applied to a small sample and a parcellated amygdala atlas
albeit at 3T was used.
The diffeomorphometrymethods described here enable transfer
of the high-ﬁeld amygdala parcellation ensuring anatomic consis-
tency. This also allows for the explicit testing of statistical signiﬁ-
cance by a subregion by subregion basis allowing us to demonstrate
the signiﬁcant changes in the affected basolateral regions. The fact
that there are signiﬁcant projections from these regions in amygdala
to hippocampus and entorhinal cortex also make it signiﬁcant in
light of our other ﬁndings in those structures in previous work
(Miller et al., 2013). Given the temporal lobe circuitry model of the
degenerative processes in MCI and AD, future studies will be
necessary to correlate shape changes in the amygdala with that in
the hippocampus, entorhinal cortex, and other structures. Such
expanded studies provide additional biomarkers to that of the
hippocampus in the early stages of MCI and AD.
5. Conclusion
In summary, application of advanced computational anatomy
diffeomorphometry methods detected atrophy in basomedial and
basolateral regions of the amygdala in patients with symptomatic
AD. Despite the small sample size, atrophied subregions of the
amygdala could be detected with p-values based on familywise
error rates which unlike false discovery rates have the advantage of
not requiring additional assumptions on the data such as inde-
pendence or positive dependence. These ﬁndings warrant further
investigation in a larger data set.
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